CureVac, GSK In Pact To Jointly Develop MRNA Vaccines For COVID-19

Source: Unsplash 

GlaxoSmithKline (GSK) and CureVac (CVAC) announced a new EUR 150M collaboration to jointly develop next-generation mRNA vaccines for COVID-19 "with the potential for a multi-valent approach to address multiple emerging variants in one vaccine."

GSK will also support the manufacture of up to 100M doses of CureVac's first-generation COVID-19 vaccine candidate CVnCoV in 2021. "Through this new exclusive co-development agreement, GSK and CureVac will contribute resources and expertise to research, develop, and manufacture a number of novel mRNA vaccine candidates, including multi-valent and monovalent approaches.

The aim of this work is to offer broader protection against a variety of different SARS-CoV2 variants and to enable a quick response to new variants potentially emerging in the future. The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval," the companies said in a statement.

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.